» Articles » PMID: 6245359

Bone-marrow Ablation and Allogeneic Marrow Transplantation in Acute Leukemia

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1980 May 8
PMID 6245359
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Thirty-three patients with acute leukemia (15 with lymphoblastic leukemia and 18 with myeloblastic leukemia) were entered into a program of high-dose radiochemotherapy followed by allogeneic bone-marrow transplantation. These patients were in various clinical stages of disease. Of 10 in complete hematologic remission at the time of transplantation, seven were alive without maintenance therapy at the time of evaluation, eight to 35 months after grafting; one was in relapse. Of 11 who received transplants during partial remission, six were in remission without further treatment eight to 33 months after transplantation. In 12 the disease was refractory to chemotherapy when preparation for transplantation was started, and only one of them was alive and free of disease after 10 months. Recurrent leukemia, graft-versus-host disease, viral pneumonia, and early therapy-related toxicity were the major causes of failure. High-dose chemotherapy and total-body irradiation followed by allogeneic marrow transplantation performed during complete or partial remission can produce long-term remission of acute leukemia.

Citing Articles

Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies.

Sieker K, Fleischmann M, Trommel M, Ramm U, Licher J, Bug G Strahlenther Onkol. 2022; 198(6):547-557.

PMID: 35318487 PMC: 9165288. DOI: 10.1007/s00066-022-01914-5.


Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Vogel J, Hui S, Hua C, Dusenbery K, Rassiah P, Kalapurakal J Front Oncol. 2021; 11:708906.

PMID: 34513689 PMC: 8428368. DOI: 10.3389/fonc.2021.708906.


Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.

Hecht A, Meyer J, Chehab F, White K, Magruder K, Dvorak C Pediatr Blood Cancer. 2019; 66(11):e27948.

PMID: 31347788 PMC: 6754267. DOI: 10.1002/pbc.27948.


Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.

Kanakry C, De Lima M, Luznik L Semin Hematol. 2015; 52(3):232-42.

PMID: 26111471 PMC: 4483196. DOI: 10.1053/j.seminhematol.2015.03.005.


Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Kharfan-Dabaja M, Labopin M, Bazarbachi A, Hamladji R, Blaise D, Socie G Bone Marrow Transplant. 2014; 49(9):1170-5.

PMID: 24978140 DOI: 10.1038/bmt.2014.133.